The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial. The main questions it aims to answer are: Does one year of treatment with ticagrelor plus aspirin (dual antiplatelet therapy) after CABG reduce the risk of major adverse cardiovascular events (MACE) over 10 years compared with aspirin alone or ticagrelor alone? What are the long-term safety outcomes, including major bleeding events, among patients who received different antiplatelet strategies? Researchers will compare the three originally randomized groups (ticagrelor plus aspirin, ticagrelor alone, and aspirin alone) to see if a one-year course of dual antiplatelet therapy provides a sustained clinical benefit over a decade. Participants will: Be contacted by telephone by the central study team for a one-time follow-up interview. Provide information about their current health status, any cardiovascular events (such as heart attack, stroke, or repeat revascularization procedures) that have occurred since the last follow-up. Report their current use of medications, including antiplatelet and other cardiovascular drugs. Allow researchers to request relevant medical records to verify any reported clinical events.
Study Type
OBSERVATIONAL
Enrollment
500
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, China
4-Point Major Adverse Cardiovascular Events (4P-MACE)
Time from randomization to the first occurrence of a composite of all-cause death, myocardial infarction, stroke, or coronary revascularization.
Time frame: From randomization to completion of 10-year follow-up
5P-MACE
Time from original randomization to the first occurrence of a composite of all-cause death, myocardial infarction, stroke, coronary repeat revascularization, or other cardiovascular-related rehospitalization.
Time frame: From randomization to completion of 10-year follow-up
3P-MACE
Time from randomization to the first occurrence of a composite of cardiovascular death, myocardial infarction, or stroke.
Time frame: From randomization to 10-year follow-up
All-Cause Death
Time from original randomization to death from any cause.
Time frame: From randomization to 10-year follow-up
Cardiovascular Death
Time from original randomization to death from cardiovascular causes, including death of unknown cause.
Time frame: From randomization to 10-year follow-up
Myocardial Infarction
Time from original randomization to the first occurrence of myocardial infarction.
Time frame: From randomization to 10-year follow-up
Stroke
Time from original randomization to the first occurrence of stroke (including ischemic and hemorrhagic stroke).
Time frame: From randomization to 10-year follow-up
Coronary Repeat Revascularization
Time from original randomization to the first occurrence of any post-procedural PCI or repeat CABG
Time frame: From randomization to 10-year follow-up
Other Cardiovascular-Related Rehospitalization
Time from original randomization to the first occurrence of hospitalization due to other cardiovascular causes besides those included in 4P-MACE, such as unstable angina, heart failure, arrhythmia, aortic syndrome, or peripheral vascular disease.
Time frame: From randomization to 10-year follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.